Solute Transporter OCTN1/Slc22a4 Affects Disease Severity and Response to Infliximab in Experimental Colitis: Role of Gut Microbiota and Immune Modulation.

RTHM-018782024Del Chierico, Federica; Masi, Letizia; Petito, Valentina; Baldelli, Valerio; Puca, Pierluigi; Benvenuto, Roberta; Fidaleo, Marco; Palucci, Ivana; Lopetuso, Loris Riccardo; Caristo, Maria Emiliana; Carrozza, Cinzia; Giustiniani, Maria Cristina; Nakamichi, Noritaka; Kato, Yukio; Putignani, Lorenza; Gasbarrini, Antonio; Pani, Giovambattista; Scaldaferri, Franco

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Solute Transporter OCTN1/Slc22a4 Affects Disease Severity and Response to Infliximab in Experimental Colitis: Role of Gut Microbiota and Immune Modulation.

Inflammatory bowel diseases, 30(12), 2259-2270

View on PubMed ↗Publisher’s paper ↗

Citation

Del Chierico, Federica; Masi, Letizia; Petito, Valentina; Baldelli, Valerio; Puca, Pierluigi; Benvenuto, Roberta; Fidaleo, Marco; Palucci, Ivana; Lopetuso, Loris Riccardo; Caristo, Maria Emiliana; Carrozza, Cinzia; Giustiniani, Maria Cristina; Nakamichi, Noritaka; Kato, Yukio; Putignani, Lorenza; Gasbarrini, Antonio; Pani, Giovambattista; Scaldaferri, Franco. (2024). Solute Transporter OCTN1/Slc22a4 Affects Disease Severity and Response to Infliximab in Experimental Colitis: Role of Gut Microbiota and Immune Modulation.. Inflammatory bowel diseases, 30(12), 2259-2270. https://doi.org/10.1093/ibd/izae135